Clonal Expansion of Stem/Progenitor Cells in Cancer, Fibrotic Diseases, and Atherosclerosis, and CD47 Protection of Pathogenic Cells

Annu Rev Med. 2022 Jan 27:73:307-320. doi: 10.1146/annurev-med-042420-104436.

Abstract

We proposed and demonstrated that myelogenous leukemia has a preleukemic phase. In the premalignant phase, normal hematopoietic stem cells (HSCs) gradually accumulate mutations leading to HSC clonal expansion, resulting in the emergence of leukemic stem cells (LSCs). Here, we show that preleukemic HSCs are the basis of clonal hematopoiesis, as well as late-onset blood diseases (chronic-phase chronic myeloid leukemia, myeloproliferative neoplasms, and myelodysplastic disease). The clones at some point each trigger surface expression of "eat me" signals for macrophages, and in the clones and their LSC progeny, this is countered by upregulation of "don't eat me" signals for macrophages such as CD47,opening the possibility of CD47-based therapies. We include evidence that similar processes result in fibroblast expansion in a variety of fibrotic diseases, and arterial smooth muscle clonal expansion is a basis of atherosclerosis, including upregulation of both "eat me" and "don't eat me" molecules on the pathogenic cells.

Keywords: atherosclerosis; clonal expansion; leukemia; myelodysplastic syndrome; premalignant progression; stem cells.

Publication types

  • Review

MeSH terms

  • Atherosclerosis*
  • CD47 Antigen
  • Hematopoietic Stem Cells
  • Humans
  • Mutation
  • Precancerous Conditions*

Substances

  • CD47 Antigen
  • CD47 protein, human